Yahoo Web Search

Search results

1. www.nejm.org › doi › fullBelantamab Mafodotin, Pomalidomide, and Dexamethasone in ...

   www.nejm.org › doi › full

   3 days ago · Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple...

2. www.nature.com › articles › s41408/024/01062-2Multiple myeloma patients with a long remission after ...

   www.nature.com › articles › s41408/024/01062-2

   May 17, 2024 · Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small...

3. www.nejm.org › doi › fullBelantamab Mafodotin, Bortezomib, and Dexamethasone for ...

   www.nejm.org › doi › full

   4 days ago · Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with...

4. cancerblog.mayoclinic.org › 2024/05/16 › advances-inAdvances in multiple myeloma treatment - Mayo Clinic ...

   cancerblog.mayoclinic.org › 2024/05/16 › advances-in

   • Cached

   May 16, 2024 · Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Black people. Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer.

5. ashpublications.org › blood › articleAntigen escape as a shared mechanism of resistance to BCMA ...

   ashpublications.org › blood › article

   • Cached

   May 10, 2024 · Key Points. Therapy-mediated loss of BCMA expression after belantamab mafodotin or anti-BCMA CAR T cells underlies teclistamab failure in RRMMLow/undetecta.

6. www.news-medical.net › news › 20240524Evolving treatment paradigms in multiple myeloma could ...

   www.news-medical.net › news › 20240524

   • Cached

   May 24, 2024 · The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug...

7. People also ask

   What is multiple myeloma?

   • Watch this "Mayo Clinic Minute" video to hear Dr. Cook discuss multiple myeloma: Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell that builds up in bone marrow. "Some of these plasma cells develop mutations over time and become abnormal and produce an abnormal protein.

   Advances in multiple myeloma treatment - Mayo Clinic Comprehensive

   cancerblog.mayoclinic.org/2024/05/16/advances-in-multiple-myeloma-treatment/

   See all results for this question

   Where can I find a clinical trial for multiple myeloma?

   • Learn more about multiple myeloma and find a clinical trial at Mayo Clinic. Join the Blood Cancers and Disorders Support Group on Mayo Clinic Connect, an online community moderated by Mayo Clinic for patients and caregivers. Also, read these articles:

   Advances in multiple myeloma treatment - Mayo Clinic Comprehensive

   cancerblog.mayoclinic.org/2024/05/16/advances-in-multiple-myeloma-treatment/

   See all results for this question

   Is multiparameter flow cytometric remission a prognostic factor for multiple myeloma patients?

   • J Clin Oncol. 2009;27:5720–6. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

   Multiple myeloma patients with a long remission after ... - Nature

   www.nature.com/articles/s41408-024-01062-2

   See all results for this question

8. www.onclive.com › view › weighing-the-benefits-andWeighing the Benefits and Limitations of CAR T-Cell Therapy ...

   www.onclive.com › view › weighing-the-benefits-and

   • Cached

   May 24, 2024 · In an interview with OncLive®, Ignatz-Hoover discussed the latest advancements in managing multiple myeloma, focusing on bispecific antibodies and CAR-T cell therapy.